Insulin– tag –
-
TechRadar Hails ‘Diabetes Breakthrough’: FDA Approves Abbott’s World’s First Dual-Sensor CGM
TechRadar UK Overview TechRadar reported the FDA's approval of Abbott's Libre Duo 10 Day as a 'diabetes breakthrough.' This is the world's first dual-sensor Continuous Glucose Monitoring (CGM) system capable of simultaneously tracking bo... -
Epocrates Explains: Ketone Tracking Integrated into CGM with First-of-its-Kind Wearable, Enhancing Diabetic Ketoacidosis Prevention
Epocrates USA Overview Epocrates reports that Abbott's Libre Duo 10 Day system is the first wearable device to integrate ketone tracking with continuous glucose monitoring (CGM). This system provides real-time ketone trend data alongside... -
FDA Authorizes First Continuous Glucose-Ketone Monitoring Wearable for Diabetes Patients Aged 2 and Older: Libre Duo 10 Day
Patient Care Online USA Overview The FDA has authorized Abbott's Libre Duo 10 Day as the first continuous glucose-ketone monitoring system for diabetes patients aged 2 and older. This landmark approval significantly enhances patient safe... -
Abbott Wins FDA Nod for World’s First Dual Glucose-Ketone Sensor, Bolstering Diabetic Ketoacidosis Prevention
MDO Online USA Overview Abbott's Libre Duo 10 Day has received FDA authorization as the world's first Continuous Glucose Monitoring (CGM) system capable of continuously tracking both glucose and ketone levels. Developed to prevent diabet... -
FDA Approves World’s First Dual Glucose-Ketone Continuous Monitoring Wearable for Diabetes Patients: Early DKA Risk Detection Enabled
GIGAZINE Japan Overview GIGAZINE reports that the U.S. FDA has approved the world's first wearable device for continuous dual glucose and ketone monitoring in diabetes patients. This is Abbott's Libre Duo 10 Day, providing real-time data... -
FDA Clears First Continuous Glucose-Ketone Monitor: Abbott’s Libre Duo 10 Day Transforms Diabetes Care
Pharmacy Times USA Overview The FDA has authorized Abbott's Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for individuals aged 2 and older with diabetes. This marks the first continuous ketone monitoring wearable in t... -
HME News Reports: Abbott Gains FDA Clearance for Dual Sensing Technology, Marking New Step in DKA Prevention
HME News USA Overview HME News reports Abbott has received FDA authorization for its Libre Duo 10 Day system, which continuously monitors both glucose and ketones. This biowearable is designed to alert patients to rising ketone levels, c... -
Dexcom’s Investment Outlook Brightens as G7 CGM Gains Expanded Reimbursement for Type 2 Non-Insulin Diabetes Patients
Seeking Alpha USA Overview Dexcom's investment thesis has significantly improved following expanded insurance reimbursement for its G7 continuous glucose monitoring (CGM) systems, now covering a large population of type 2 non-insulin dia... -
UAE Breakthrough: Wearable Ketone Monitor Slashes DKA Emergencies by 60% for Type 1 Diabetics, Poised to Revolutionize Diabetes Management
Facebook UAE Overview Researchers in the UAE have engineered a pioneering wearable continuous ketone monitor (CKM) that tracks interstitial fluid ketone levels to avert diabetic ketoacidosis (DKA) in Type 1 diabetics. A clinical trial in... -
Vertex Pharmaceuticals Initiates Phase 3 Trial for iPSC Islet Cell Therapy VX-880 for Type 1 Diabetes, Showing High Rates of Insulin Independence
Facebook (Breakthrough T1D) USA Overview Vertex Pharmaceuticals has launched a Phase 3 clinical trial for zimislecel (VX-880), its stem cell-derived islet cell therapy for severe type 1 diabetes. Prior trials demonstrated remarkable effi...
